Endothelins (Endothelin)

Subscribe to Selected New Research on Endothelins

3478 relevant articles (91 outcomes, 499 trials/studies) found for this Bio-Agent

Description: 21-Amino-acid peptides produced by vascular endothelial cells and functioning as potent vasoconstrictors. The endothelin family consists of three members, ENDOTHELIN-1; ENDOTHELIN-2; and ENDOTHELIN-3. All three peptides contain 21 amino acids, but vary in amino acid composition. The three peptides produce vasoconstrictor and pressor responses in various parts of the body. However, the quantitative profiles of the pharmacological activities are considerably different among the three isopeptides.

Also Known As:

Endothelin; Vasoconstrictor Factors, Endothelium-Derived; Endothelium-Derived Vasoconstrictor Factors

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Experts

1.	Webb, D J: 9 articles (03/2008 - 01/2000)
2.	Barton, Matthias: 9 articles (12/2007 - 08/2002)
3.	Wülfing, Pia: 7 articles (09/2008 - 09/2003)
4.	Bagnato, Anna: 7 articles (08/2008 - 02/2003)
5.	Wülfing, Christian: 7 articles (07/2007 - 09/2003)
6.	Schiffrin, Ernesto L: 7 articles (06/2005 - 01/2003)
7.	Traupe, Tobias: 6 articles (08/2005 - 08/2002)
8.	Shaw, S: 6 articles (06/2001 - 01/2000)
9.	Rosanò, Laura: 5 articles (08/2008 - 12/2005)
10.	Hocher, Berthold: 5 articles (08/2008 - 02/2003)

Related Diseases

1.	Heart Failure 06/01/2008 - "Our results suggest that, in congestive heart failure, ETB receptors are essential to limit circulating endothelin levels, which may argue for improved cardiac benefits after long-term treatment with highly selective ETA-receptor antagonists." 01/01/2006 - "The positive inotropic agents have thrown their last reserves into the fight against cardiac failure: the anti-endothelins have not yet been shown to have significant benefits. " 12/01/2001 - "Given its pharmacological profile, it is likely that endothelin (ET-1) plays a deleterious role in the development of heart failure, and that blockers of the endothelin system are beneficial in this disease. " 07/01/2000 - "Total endothelin immunoreactivity was non significantly greater in heart failure patients than controls (6. 8+/-1.4 vs. 4.6+/-0.5 pM; P=0.13). " 06/01/2001 - "The RITZ-2 trial suggests that an intravenous, non-selective endothelin antagonist is effective in improving haemodynamics and symptoms and possibly in reducing morbidity in severe heart failure. " Order ALL the reference details at left...
2.	Pulmonary Hypertension (Ayerza Syndrome) 10/01/2007 - "Several studies have suggested that interfering with the function of the endothelin system will be helpful in pulmonary hypertension treatment. " 03/01/2006 - "STUDY OBJECTIVES: Endothelin (ET)-1 is a mediator of vascular remodeling seen in human pulmonary hypertension (PH), and it is normally cleared via endothelial ET-B receptors. " 12/01/1998 - "Endothelin antagonists also offer promise in a rapidly fatal condition, primary pulmonary hypertension. " 09/01/1999 - "The aim of the study was to assess plasma endothelin concentration in patients with pulmonary hypertension. " 04/01/1996 - "OBJECTIVE: To study the synthesis and distribution of endothelin (ET) in the rat model of pulmonary hypertension (PH). " Order ALL the reference details at left...
3.	Hypertension (High Blood Pressure) 11/01/2008 - "Blockade of the endothelin (ET) system is beneficial in pulmonary arterial hypertension (PAH). " 05/01/2009 - "We found previously that selective blockade of endothelin ETA receptors is superior to nonselective ET(A)/ET(B) in attenuating hypertension and survival rate in Ren-2 transgenic rats (TGR). " 11/01/2000 - "From these results, we suggest that: (1) the contribution of endothelin (ET) to the maintenance of hypertension is greater in salt-sensitive hypertensive models than in SHR and SHRSP; (2) the antihypertensive efficacy of ETA/ETB blockade is augmented by AT1-receptor blockade; (3) ET blockers alone or in combination with AT1 antagonists could be useful in the treatment of hypertension for patients who do not respond adequately to renin-angiotensin system inhibitors alone." 10/01/2004 - "However, to date no substantial clinical efficacy of endothelin-I receptor blockers has been shown in patients with essential hypertension. " 07/01/1997 - "Failure of some experimental models of hypertension to respond to treatment with the combined ETA/ETB endothelin antagonist may be due in part to blockade of vasorelaxant endothelial ETB receptors which could in theory reduce the efficacy of endothelin antagonism. " Order ALL the reference details at left...
4.	Acute Kidney Failure (Acute Renal Failure) 04/01/2001 - "Endothelin (ET) receptor antagonists have proved beneficial in the treatment of ischemic acute renal failure (IARF); however, the long-term outcomes have not been assessed in this disease. " 01/01/1994 - "Clearly the development of specific TNF and endothelin antagonists holds out promise for the treatment and prevention of septic acute renal failure." 10/01/2005 - "As the endothelin pathway is known to be involved in the development of acute renal failure (ARF), we designed a study to clarify its role in ARF following OLT. " 11/01/1995 - "During the study of the pathological significance of circulating endothelin (ET) in acute renal failure (ARF) we measured ET in 7 children (mean age 8.8+4.4 years) with ARF in the most severe phase, and 3.7+3.5 months later in the recovery period. " 04/01/1992 - "[Endothelin and acute renal failure: study on their relation and possible mechanisms]" Order ALL the reference details at left...
5.	Inflammation 10/01/2005 - "The role of endothelin in cardiac remodeling and inflammation may be important in the progression of failure, and endothelin antagonists may be beneficial in treatment in combination with drugs already in use." 02/01/2000 - "In this study, we demonstrated a role for endogenous endothelins in eosinophil and T lymphocyte recruitment and cytokine secretion in a murine model of allergic inflammation. " 11/01/1999 - "Animal studies show elevation of ET-1 during experimental airway inflammation, and inhibition of inflammation by endothelin-antagonists, suggesting pro-inflammatory activity for ET-1. " 10/31/2007 - "Endothelin (ET) receptor antagonists have been developed to produce a reduction of ET related effects in various diseases, as well as in animal models of airway inflammation. " 01/01/2007 - "This article reviews the role of endothelin as an example of a pleiotropic mediator with effects on various aspects of SSc pathogenesis, such as inflammation, vasculopathy and tissue remodelling." Order ALL the reference details at left...

Related Drugs and Biologics

1.	bosentan (Tracleer)
2.	Endothelin Receptors (Endothelin Receptor)
3.	Epoprostenol (Prostacyclin)
4.	Nitric Oxide (Nitrogen Monoxide)
5.	Renin
6.	cyclo(Trp-Asp-Pro-Val-Leu)
7.	Endothelins (Endothelin)
8.	TAK 044
9.	tezosentan
10.	Angiotensin II

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Aftercare (After-Treatment)
3.	Lung Transplantation
4.	Ligation
5.	Homologous Transplantation (Allograft)

Best Treatments:
Research Summary Report
on Heart Failure

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2790 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>